PMID- 30628185
OWN - NLM
STAT- MEDLINE
DCOM- 20200326
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 8
IP  - 2
DP  - 2019 Feb
TI  - Nivolumab provides improved effectiveness and safety compared with docetaxel as a 
      second-line treatment for advanced non-small cell lung cancer: A systematic 
      review and meta-analysis.
PG  - 629-642
LID - 10.1002/cam4.1966 [doi]
AB  - BACKGROUND: As an inhibitor of programmed death-1 (PD-1) protein, nivolumab has 
      been shown to be effective in various cancers. We thus conducted this 
      meta-analysis to compare the relative efficacy of nivolumab vs docetaxel-based 
      chemotherapy as a second-line treatment for previously treated advanced non-small 
      cell lung cancer (NSCLC). METHODS: Relevant studies were identified through 
      searches of databases and conference proceedings. Progression-free survival 
      (PFS), overall survival (OS), drug responses, and adverse effects (AEs) were 
      assessed as the primary endpoints. RESULTS: After screening, we included six 
      studies (949 patients) in the final analysis. Nivolumab showed better efficacy in 
      terms of the PFS (hazard ratios [HR]: 0.70, P = 0.03), OS (HR: 0.70, 
      P < 0.00001), objective response rate (ORR) (risk ratios [RR]: 1.73, P = 0.0008), 
      total AEs (RR: 0.77, P = 0.006), and grade 3-5 AEs (RR: 0.18, P < 0.00001) than 
      docetaxel. The anti-tumor efficacy of nivolumab for NSCLC in terms of both PFS 
      and OS was positively correlated with the level of PD-L1 expression. In the 
      nivolumab treatment arm, the 10 most-reported AEs were fatigue (15.7%), nausea 
      (10.8%), decreased appetite (10.3%), asthenia (9.8%), diarrhea (7.5%), rash 
      (7.5%), arthralgia (5.4%), vomiting (4.4%), constipation (3.5%), and pyrexia 
      (3.3%). CONCLUSIONS: For advanced NSCLC, nivolumab is a better therapy in terms 
      of both anti-tumor efficacy and safety than docetaxel-based chemotherapy. More 
      high-quality randomized controlled trials are needed to confirm these results.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Xu, Zheng
AU  - Xu Z
AD  - Department of Cardio-Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Yu, Dongliang
AU  - Yu D
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Xu, Jianjun
AU  - Xu J
AD  - Department of Cardio-Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AUID- ORCID: 0000-0003-2962-0847
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190109
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 15H5577CQD (Docetaxel)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cohort Studies
MH  - Docetaxel/adverse effects/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Nivolumab/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC6382729
OTO - NOTNLM
OT  - chemotherapy
OT  - docetaxel
OT  - meta-analysis
OT  - nivolumab
OT  - non-small cell lung cancer
EDAT- 2019/01/11 06:00
MHDA- 2020/03/27 06:00
PMCR- 2019/01/09
CRDT- 2019/01/11 06:00
PHST- 2018/09/13 00:00 [received]
PHST- 2018/11/26 00:00 [revised]
PHST- 2018/12/18 00:00 [accepted]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2020/03/27 06:00 [medline]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2019/01/09 00:00 [pmc-release]
AID - CAM41966 [pii]
AID - 10.1002/cam4.1966 [doi]
PST - ppublish
SO  - Cancer Med. 2019 Feb;8(2):629-642. doi: 10.1002/cam4.1966. Epub 2019 Jan 9.